Nurix Therapeutics, Inc. NRIX
NASDAQ
| 08/31/2026 | 05/31/2026 | 02/28/2026 | 11/30/2025 | 08/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 8,426.27% | -79.47% | -66.12% | 2.21% | -37.29% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 8,426.27% | -79.47% | -66.12% | 2.21% | -37.29% |
| Cost of Revenue | -7.97% | 12.24% | 20.78% | 23.50% | 55.22% |
| Gross Profit | 859.09% | -130.93% | -52.09% | -28.75% | -82.37% |
| SG&A Expenses | 161.06% | 9.19% | 25.36% | 27.35% | 12.30% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 14.44% | 11.77% | 21.43% | 24.03% | 47.74% |
| Operating Income | 712.19% | -94.95% | -47.14% | -28.52% | -67.34% |
| Income Before Tax | 751.94% | -110.30% | -54.70% | -33.62% | -76.82% |
| Income Tax Expenses | -- | -135.66% | -- | -100.00% | -- |
| Earnings from Continuing Operations | 736.20% | -106.00% | -54.70% | -33.60% | -76.53% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 736.20% | -106.00% | -54.70% | -33.60% | -76.53% |
| EBIT | 712.19% | -94.95% | -47.14% | -28.52% | -67.34% |
| EBITDA | 728.48% | -99.54% | -49.22% | -28.65% | -71.13% |
| EPS Basic | 579.91% | -55.54% | -17.44% | -10.16% | -52.65% |
| Normalized Basic EPS | 591.80% | -58.80% | -17.44% | -10.18% | -52.92% |
| EPS Diluted | 559.22% | -55.54% | -17.44% | -10.16% | -53.11% |
| Normalized Diluted EPS | 572.36% | -58.80% | -17.44% | -10.18% | -52.92% |
| Average Basic Shares Outstanding | 32.56% | 32.43% | 31.73% | 21.27% | 15.64% |
| Average Diluted Shares Outstanding | 38.02% | 32.43% | 31.73% | 21.27% | 15.64% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |